首页 > 最新文献

Taiwanese Journal of Obstetrics & Gynecology最新文献

英文 中文
Fine-tuning Llama-2-13B with AI-generated medical diagnoses: A novel strategy for optimizing ICD coding in gynecologic oncology 微调lama-2- 13b与人工智能生成的医疗诊断:优化妇科肿瘤ICD编码的新策略
IF 2.2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-11-01 DOI: 10.1016/j.tjog.2025.02.006
Yu-Ling Liang , Chiu-Fan Chen , Meng-Hsing Wu , Keng-Fu Hsu , Po-Ting Chang , Yuan-Jhe Chuang , Po-Fan Chen

Objective

Given the substantial advancements in Large Language Models (LLMs), this study aimed to explore the effectiveness of using AI-generated medical diagnoses in the fine-tuning of the Llama-2 model, with the objective of optimizing the ICD10 coding process for gynecologic oncology. This study aimed to fine-tune the Llama-2-13B model using AI-generated diagnostic texts based on ICD10 descriptors, focusing on gynecologic oncology for initial validation.

Materials and methods

AI-generated diagnostic texts were rigorously confirmed to ensure medical coherence and reliability for fine-tuning. Four models were established: The original Llama-2-13B (Model 1); a model fine-tuned with basic ICD10 codes (Model 2); a model trained with an additional set of 10 AI-generated diagnosis statements per ICD10 code (Model 3); and the forth model trained with an additional set of 20 AI-generated statements per code (Model 4). Validation involved a set of 83 discharge records related to gynecologic oncology, derived from 2415 discharge records collected from January 1, 2020, and June 30, 2023.

Results

Validation results for the models showed significant improvement in the accuracy rates and Kappa scores: Model 1 (native Llama-2-13B) had an accuracy of 0.06 and a Kappa score of 0.04, Model 2 achieved 0.24 and 0.19, Model 3 reached 0.90 and 0.89, and Model 4 greatly improved to 0.95 and 0.94.

Conclusion

The use of prompts to generate diagnostic descriptions, coupled with AI-generated data for model fine-tuning, resulted in a substantial enhancement in the Llama-2-13B model’s capability to accurately determine ICD diagnostic codes from medical records. This methodology offers a cost-effective strategy, optimizes model accuracy, and underscores the potential for broader applications due to the LLM’s generative capabilities.
鉴于大型语言模型(Large Language Models, LLMs)的巨大进步,本研究旨在探索利用人工智能生成的医学诊断对lama-2模型进行微调的有效性,以优化妇科肿瘤ICD10编码过程。本研究旨在使用基于ICD10描述符的人工智能生成的诊断文本对lama-2- 13b模型进行微调,重点是妇科肿瘤学进行初步验证。材料和方法严格确认ai生成的诊断文本,以确保微调的医学一致性和可靠性。建立了四种模型:原羊驼-2- 13b(模型1);使用基本ICD10代码进行微调的模型(模型2);每个ICD10代码使用一组额外的10个ai生成的诊断语句训练的模型(模型3);第四个模型使用每个代码额外的20条人工智能生成的语句进行训练(模型4)。验证涉及一组83份与妇科肿瘤相关的出院记录,这些记录来自于2020年1月1日至2023年6月30日收集的2415份出院记录。结果模型的验证结果显示,模型1的准确率为0.06,Kappa评分为0.04,模型2的准确率为0.24,Kappa评分为0.19,模型3的准确率为0.90,Kappa评分为0.89,模型4的准确率为0.95,Kappa评分为0.94。使用提示生成诊断描述,再加上人工智能生成的模型微调数据,使得lama-2- 13b模型从医疗记录中准确确定ICD诊断代码的能力大大增强。这种方法提供了一种经济有效的策略,优化了模型的准确性,并且由于LLM的生成能力,强调了更广泛应用的潜力。
{"title":"Fine-tuning Llama-2-13B with AI-generated medical diagnoses: A novel strategy for optimizing ICD coding in gynecologic oncology","authors":"Yu-Ling Liang ,&nbsp;Chiu-Fan Chen ,&nbsp;Meng-Hsing Wu ,&nbsp;Keng-Fu Hsu ,&nbsp;Po-Ting Chang ,&nbsp;Yuan-Jhe Chuang ,&nbsp;Po-Fan Chen","doi":"10.1016/j.tjog.2025.02.006","DOIUrl":"10.1016/j.tjog.2025.02.006","url":null,"abstract":"<div><h3>Objective</h3><div>Given the substantial advancements in Large Language Models (LLMs), this study aimed to explore the effectiveness of using AI-generated medical diagnoses in the fine-tuning of the Llama-2 model, with the objective of optimizing the ICD10 coding process for gynecologic oncology. This study aimed to fine-tune the Llama-2-13B model using AI-generated diagnostic texts based on ICD10 descriptors, focusing on gynecologic oncology for initial validation.</div></div><div><h3>Materials and methods</h3><div>AI-generated diagnostic texts were rigorously confirmed to ensure medical coherence and reliability for fine-tuning. Four models were established: The original Llama-2-13B (Model 1); a model fine-tuned with basic ICD10 codes (Model 2); a model trained with an additional set of 10 AI-generated diagnosis statements per ICD10 code (Model 3); and the forth model trained with an additional set of 20 AI-generated statements per code (Model 4). Validation involved a set of 83 discharge records related to gynecologic oncology, derived from 2415 discharge records collected from January 1, 2020, and June 30, 2023.</div></div><div><h3>Results</h3><div>Validation results for the models showed significant improvement in the accuracy rates and Kappa scores: Model 1 (native Llama-2-13B) had an accuracy of 0.06 and a Kappa score of 0.04, Model 2 achieved 0.24 and 0.19, Model 3 reached 0.90 and 0.89, and Model 4 greatly improved to 0.95 and 0.94.</div></div><div><h3>Conclusion</h3><div>The use of prompts to generate diagnostic descriptions, coupled with AI-generated data for model fine-tuning, resulted in a substantial enhancement in the Llama-2-13B model’s capability to accurately determine ICD diagnostic codes from medical records. This methodology offers a cost-effective strategy, optimizes model accuracy, and underscores the potential for broader applications due to the LLM’s generative capabilities.</div></div>","PeriodicalId":49449,"journal":{"name":"Taiwanese Journal of Obstetrics & Gynecology","volume":"64 6","pages":"Pages 978-984"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145475770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Embracing the future: NOTES as the next evolution in surgical practice 拥抱未来:NOTES作为外科实践的下一个发展
IF 2.2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-11-01 DOI: 10.1016/j.tjog.2025.07.021
Chyi-Long Lee
{"title":"Embracing the future: NOTES as the next evolution in surgical practice","authors":"Chyi-Long Lee","doi":"10.1016/j.tjog.2025.07.021","DOIUrl":"10.1016/j.tjog.2025.07.021","url":null,"abstract":"","PeriodicalId":49449,"journal":{"name":"Taiwanese Journal of Obstetrics & Gynecology","volume":"64 6","pages":"Pages 949-950"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145475949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High percentage of NK count in peripheral blood could be an important clue for the case with recurrent implantation failure 外周血NK计数高可能是反复植入失败的重要线索
IF 2.2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-11-01 DOI: 10.1016/j.tjog.2025.04.023
Kuan-Yu Chen, Chung-Jen Chen
{"title":"High percentage of NK count in peripheral blood could be an important clue for the case with recurrent implantation failure","authors":"Kuan-Yu Chen,&nbsp;Chung-Jen Chen","doi":"10.1016/j.tjog.2025.04.023","DOIUrl":"10.1016/j.tjog.2025.04.023","url":null,"abstract":"","PeriodicalId":49449,"journal":{"name":"Taiwanese Journal of Obstetrics & Gynecology","volume":"64 6","pages":"Page 1128"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145476075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The sFlt-1/PlGF ratio of high-risk pregnant women for preeclampsia compared in singleton, twin, and triplet pregnancies 高危孕妇子痫前期的sFlt-1/PlGF比值与单胎、双胎和三胞胎妊娠的比较
IF 2.2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-11-01 DOI: 10.1016/j.tjog.2025.07.023
Hyeon Ji Kim , Da Eun Jeong , Eun Jin Choi , Na Young Kim , Min Jung Lee , Bo Young Choi , Jee Yoon Park

Objective

To evaluate the predictive performance of the soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) ratio for preeclampsia across singleton, twin, and triplet pregnancies.

Materials and methods

A retrospective cohort study was performed in pregnant women who had sFlt-1/PlGF testing and delivered at Seoul National University Bundang Hospital from March 2019 to December 2023. Maternal characteristics and obstetric outcomes were reviewed, and patients were classified into singleton, twin, and triplet pregnancies. The predictive performance of the sFlt-1/PlGF ratio was assessed using logistic regression and receiver operating characteristic (ROC) curve analysis. Clinically validated cut-off values from the NICE guideline were applied.

Results

Among 773 patients (288 singletons, 469 twins, and 16 triplets), preeclampsia was diagnosed in 55.9 %, 29.4 %, and 62.5 % of cases, respectively. In singleton pregnancies, 81.4 % of preeclampsia cases had an sFlt-1/PlGF ratio >38, and 73.3 % had a ratio >85, compared to 68.1 % and 32.6 % in twins. For preeclampsia before 34 weeks, the sFlt-1/PlGF ratio was significantly lower in twin and triplet pregnancies than in singletons (both p < 0.05). The predictive value of the sFlt-1/PlGF ratio was highest in singleton pregnancies, with an area under the curve (AUC) of 0.870 [95 % Confidence interval (CI) = 0.826–0.914] for preeclampsia before 34 weeks, compared to 0.789 [95 % CI = 0.717–0.862] in twins and 0.813 [95 % CI = 0.592–1.033] in triplets. At the predefined cut-off of 85, logistic regression confirmed that an sFlt-1/PlGF ratio >85 was significantly associated with preeclampsia before 34 weeks in singletons (OR = 16.06, 95 % CI = 8.75–29.49, p < 0.001) and still significant in twins (OR = 3.66, 95 % CI = 1.74–7.69, p = 0.001), but not in triplets.

Conclusions

While the sFlt-1/PlGF ratio remains a valuable biomarker for preeclampsia prediction in singleton and twin pregnancies, its clinical utility in triplet pregnancies is limited. Further large-scale studies are needed to establish optimal cut-off values for multifetal pregnancies, particularly in triplets, to enhance risk stratification and clinical application.
目的评价可溶性膜样酪氨酸激酶1 (sFlt-1)与胎盘生长因子(PlGF)比值对单胎、双胎和三胞胎妊娠子痫前期的预测作用。材料与方法对2019年3月至2023年12月在首尔国立大学盆唐医院进行sFlt-1/PlGF检测的孕妇进行回顾性队列研究。回顾了产妇特征和产科结局,并将患者分为单胎、双胎和三胞胎妊娠。采用logistic回归和受试者工作特征(ROC)曲线分析评估sFlt-1/PlGF比值的预测性能。采用NICE指南中经临床验证的临界值。结果773例患者(单胎288例,双胞胎469例,三胞胎16例)中,先兆子痫的诊断率分别为55.9%、29.4%和62.5%。在单胎妊娠中,81.4%的先兆子痫患者的sFlt-1/PlGF比值为38,73.3%的患者的sFlt-1/PlGF比值为85,而双胞胎患者的sFlt-1/PlGF比值为68.1%和32.6%。对于34周前子痫前期,双胎和三胞胎妊娠的sFlt-1/PlGF比值显著低于单胎(p < 0.05)。单胎妊娠sFlt-1/PlGF比值的预测值最高,34周前子痫前期的曲线下面积(AUC)为0.870[95%可信区间(CI) = 0.826-0.914],双胞胎为0.789 [95% CI = 0.717-0.862],三胞胎为0.813 [95% CI = 0.592-1.033]。在预先设定的截止值85时,逻辑回归证实sFlt-1/PlGF比值>;85与单胎34周前的先兆子痫显著相关(OR = 16.06, 95% CI = 8.75-29.49, p < 0.001),在双胞胎中仍然显著相关(OR = 3.66, 95% CI = 1.74-7.69, p = 0.001),但在三胞胎中不显著。结论虽然sFlt-1/PlGF比值仍然是单胎和双胎妊娠子痫前期预测的有价值的生物标志物,但其在三胞胎妊娠中的临床应用有限。需要进一步的大规模研究来确定多胎妊娠,特别是三胞胎妊娠的最佳临界值,以加强风险分层和临床应用。
{"title":"The sFlt-1/PlGF ratio of high-risk pregnant women for preeclampsia compared in singleton, twin, and triplet pregnancies","authors":"Hyeon Ji Kim ,&nbsp;Da Eun Jeong ,&nbsp;Eun Jin Choi ,&nbsp;Na Young Kim ,&nbsp;Min Jung Lee ,&nbsp;Bo Young Choi ,&nbsp;Jee Yoon Park","doi":"10.1016/j.tjog.2025.07.023","DOIUrl":"10.1016/j.tjog.2025.07.023","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the predictive performance of the soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) ratio for preeclampsia across singleton, twin, and triplet pregnancies.</div></div><div><h3>Materials and methods</h3><div>A retrospective cohort study was performed in pregnant women who had sFlt-1/PlGF testing and delivered at Seoul National University Bundang Hospital from March 2019 to December 2023. Maternal characteristics and obstetric outcomes were reviewed, and patients were classified into singleton, twin, and triplet pregnancies. The predictive performance of the sFlt-1/PlGF ratio was assessed using logistic regression and receiver operating characteristic (ROC) curve analysis. Clinically validated cut-off values from the NICE guideline were applied.</div></div><div><h3>Results</h3><div>Among 773 patients (288 singletons, 469 twins, and 16 triplets), preeclampsia was diagnosed in 55.9 %, 29.4 %, and 62.5 % of cases, respectively. In singleton pregnancies, 81.4 % of preeclampsia cases had an sFlt-1/PlGF ratio &gt;38, and 73.3 % had a ratio &gt;85, compared to 68.1 % and 32.6 % in twins. For preeclampsia before 34 weeks, the sFlt-1/PlGF ratio was significantly lower in twin and triplet pregnancies than in singletons (both p &lt; 0.05). The predictive value of the sFlt-1/PlGF ratio was highest in singleton pregnancies, with an area under the curve (AUC) of 0.870 [95 % Confidence interval (CI) = 0.826–0.914] for preeclampsia before 34 weeks, compared to 0.789 [95 % CI = 0.717–0.862] in twins and 0.813 [95 % CI = 0.592–1.033] in triplets. At the predefined cut-off of 85, logistic regression confirmed that an sFlt-1/PlGF ratio &gt;85 was significantly associated with preeclampsia before 34 weeks in singletons (OR = 16.06, 95 % CI = 8.75–29.49, p &lt; 0.001) and still significant in twins (OR = 3.66, 95 % CI = 1.74–7.69, p = 0.001), but not in triplets.</div></div><div><h3>Conclusions</h3><div>While the sFlt-1/PlGF ratio remains a valuable biomarker for preeclampsia prediction in singleton and twin pregnancies, its clinical utility in triplet pregnancies is limited. Further large-scale studies are needed to establish optimal cut-off values for multifetal pregnancies, particularly in triplets, to enhance risk stratification and clinical application.</div></div>","PeriodicalId":49449,"journal":{"name":"Taiwanese Journal of Obstetrics & Gynecology","volume":"64 6","pages":"Pages 996-1003"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145475632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on “Successful management of a pregnancy women with sudden onset of acute pancreatitis: A case report and literature review” 《妊娠妇女突发性急性胰腺炎的成功治疗1例报告及文献复习》
IF 2.2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-11-01 DOI: 10.1016/j.tjog.2025.07.026
Fenglin Jiang
{"title":"Comment on “Successful management of a pregnancy women with sudden onset of acute pancreatitis: A case report and literature review”","authors":"Fenglin Jiang","doi":"10.1016/j.tjog.2025.07.026","DOIUrl":"10.1016/j.tjog.2025.07.026","url":null,"abstract":"","PeriodicalId":49449,"journal":{"name":"Taiwanese Journal of Obstetrics & Gynecology","volume":"64 6","pages":"Page 1129"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145476076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prenatal diagnosis of a familial 16p13.11 microduplication with no apparently phenotypic abnormality in the family carrier members 家族16p13.11微重复的产前诊断,在家族携带者成员中没有明显的表型异常
IF 2.2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-11-01 DOI: 10.1016/j.tjog.2025.09.009
Chih-Ping Chen
{"title":"Prenatal diagnosis of a familial 16p13.11 microduplication with no apparently phenotypic abnormality in the family carrier members","authors":"Chih-Ping Chen","doi":"10.1016/j.tjog.2025.09.009","DOIUrl":"10.1016/j.tjog.2025.09.009","url":null,"abstract":"","PeriodicalId":49449,"journal":{"name":"Taiwanese Journal of Obstetrics & Gynecology","volume":"64 6","pages":"Pages 1102-1103"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145475636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Plasma level of cancer stem cell marker aldehyde dehydrogenase 1 (ALDH1) is higher in locally advance cervical cancer 局部进展期宫颈癌患者血浆中肿瘤干细胞标志物醛脱氢酶1 (ALDH1)水平升高
IF 2.2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-11-01 DOI: 10.1016/j.tjog.2025.01.012
I Nyoman Budiana , Pande Kadek Aditya Prayudi , I Nyoman Bayu Mahendra , Ni Putu Sri Indrani Remitha , I Gede Krisna Arim Sadeva , I Gede Putu Supadmanaba

Objective

This study is aimed to examine the plasma level of ALDH1 in early and locally advanced cervical cancer (CC) patients and to investigate its association with the presence of prognostic factors for recurrence in early stage.

Material and methods

This is a cross-sectional study involving 82 patients with CC (33 patients with early stage IB-IIA and 49 patients with locally advance/LACC stage IIB-IVA) who were admitted to Gynecologic Oncology Clinic, Prof. dr. I G.N.G. Ngoerah Hospital Denpasar from September 2022 to April 2023. Prognostic factors for recurrence were recorded from early-stage CC after radical hysterectomy. Pre-treatment plasma level of ALDH1 was determined using ALDH1 ELISA kit (cat. no. E3259Hu).

Results

Plasma level of ALDH1 was significantly higher in patients with LACC as compared to early-stage CC (median: 7.0 vs. 4.3 ng/ml, p < 0.001). In early-stage CC, higher plasma level of ALDH1 was also associated with bulkier tumor mass (≥4 cm) (OR 9.2, 95 % CI 1.3–63.1, p = 0.001; threshold value 4.0 ng/ml, AUC 0.821, p-value = 0.002). However, plasma level of ALDH1 was not associated with the histologic subtype, the presence of LVSI, or status of the vaginal margins (p-value >0.05).

Conclusion

Increasing plasma level of ALDH1 in CC patients was associated with more advance stage and bulkier tumor mass. Our finding suggests that in the clinical setting, evaluating the plasma level of ALDH1 may aid in assessing the progression of cervical cancer. Future study such as longer-term longitudinal study with larger sample size is needed to explore the association between ALDH1 expression and the clinical response to treatment (e.g., chemoradiation) or risk of recurrence in early-stage CC patients.
目的探讨早期和局部晚期宫颈癌(CC)患者血浆ALDH1水平与早期复发预后因素的关系。材料和方法这是一项横断面研究,涉及82名CC患者(33名早期IB-IIA患者和49名局部进展/LACC期ib - iva患者),这些患者于2022年9月至2023年4月在登巴萨Ngoerah医院妇科肿瘤诊所I G.N.G.博士教授入住。记录根治性子宫切除术后早期CC复发的预后因素。采用ALDH1酶联免疫吸附测定试剂盒(cat。否。E3259Hu)。结果LACC患者血浆ALDH1水平明显高于早期CC(中位数:7.0 vs. 4.3 ng/ml, p < 0.001)。在早期CC中,较高的血浆ALDH1水平也与较大的肿瘤肿块(≥4 cm)相关(OR 9.2, 95% CI 1.3-63.1, p = 0.001;阈值4.0 ng/ml, AUC 0.821, p = 0.002)。然而,血浆ALDH1水平与组织学亚型、LVSI存在或阴道边缘状态无关(p值>;0.05)。结论肝癌患者血浆ALDH1水平升高与肿瘤进展期越早、肿瘤体积越大有关。我们的发现提示,在临床环境中,评估血浆ALDH1水平可能有助于评估宫颈癌的进展。未来的研究,如更大样本量的长期纵向研究,需要探索ALDH1表达与早期CC患者对治疗(如放化疗)的临床反应或复发风险之间的关系。
{"title":"Plasma level of cancer stem cell marker aldehyde dehydrogenase 1 (ALDH1) is higher in locally advance cervical cancer","authors":"I Nyoman Budiana ,&nbsp;Pande Kadek Aditya Prayudi ,&nbsp;I Nyoman Bayu Mahendra ,&nbsp;Ni Putu Sri Indrani Remitha ,&nbsp;I Gede Krisna Arim Sadeva ,&nbsp;I Gede Putu Supadmanaba","doi":"10.1016/j.tjog.2025.01.012","DOIUrl":"10.1016/j.tjog.2025.01.012","url":null,"abstract":"<div><h3>Objective</h3><div>This study is aimed to examine the plasma level of ALDH1 in early and locally advanced cervical cancer (CC) patients and to investigate its association with the presence of prognostic factors for recurrence in early stage.</div></div><div><h3>Material and methods</h3><div>This is a cross-sectional study involving 82 patients with CC (33 patients with early stage IB-IIA and 49 patients with locally advance/LACC stage IIB-IVA) who were admitted to Gynecologic Oncology Clinic, Prof. dr. I G.N.G. Ngoerah Hospital Denpasar from September 2022 to April 2023. Prognostic factors for recurrence were recorded from early-stage CC after radical hysterectomy. Pre-treatment plasma level of ALDH1 was determined using ALDH1 ELISA kit (cat. no. E3259Hu).</div></div><div><h3>Results</h3><div>Plasma level of ALDH1 was significantly higher in patients with LACC as compared to early-stage CC (median: 7.0 vs. 4.3 ng/ml, p &lt; 0.001). In early-stage CC, higher plasma level of ALDH1 was also associated with bulkier tumor mass (≥4 cm) (OR 9.2, 95 % CI 1.3–63.1, p = 0.001; threshold value 4.0 ng/ml, AUC 0.821, p-value = 0.002). However, plasma level of ALDH1 was not associated with the histologic subtype, the presence of LVSI, or status of the vaginal margins (p-value &gt;0.05).</div></div><div><h3>Conclusion</h3><div>Increasing plasma level of ALDH1 in CC patients was associated with more advance stage and bulkier tumor mass. Our finding suggests that in the clinical setting, evaluating the plasma level of ALDH1 may aid in assessing the progression of cervical cancer. Future study such as longer-term longitudinal study with larger sample size is needed to explore the association between ALDH1 expression and the clinical response to treatment (e.g., chemoradiation) or risk of recurrence in early-stage CC patients.</div></div>","PeriodicalId":49449,"journal":{"name":"Taiwanese Journal of Obstetrics & Gynecology","volume":"64 6","pages":"Pages 1050-1055"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145475696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prenatal diagnosis of a familial 4q35.1q35.2 microdeletion associated with no apparently phenotypic abnormality in the family carrier members 产前诊断家族性4q35.1q35.2微缺失与家族携带者成员无明显表型异常相关
IF 2.2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-11-01 DOI: 10.1016/j.tjog.2025.09.008
Chih-Ping Chen
{"title":"Prenatal diagnosis of a familial 4q35.1q35.2 microdeletion associated with no apparently phenotypic abnormality in the family carrier members","authors":"Chih-Ping Chen","doi":"10.1016/j.tjog.2025.09.008","DOIUrl":"10.1016/j.tjog.2025.09.008","url":null,"abstract":"","PeriodicalId":49449,"journal":{"name":"Taiwanese Journal of Obstetrics & Gynecology","volume":"64 6","pages":"Pages 1100-1101"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145475635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Functional analysis of PHLDA2 in ovarian cancer: Effects on tumor cell behavior and autophagy PHLDA2在卵巢癌中的功能分析:对肿瘤细胞行为和自噬的影响
IF 2.2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-11-01 DOI: 10.1016/j.tjog.2025.08.003
Ren Xu , Luyang Su , Yanan Ren , Xinjun Li , Shuo Xu , Jianzhi Su

Objective

We aimed to explore the effect of PHLDA2 on the biological behavior of ovarian cancer (OC) cell in vitro.

Materials and methods

Validation of PHLDA2 mRNA expression based on the analysis from GEPIA was performed on clinical OC tissues using qPCR. SiRNA-mediated knockdown of PHLDA2 was conducted in OC cells to investigate its potential functions. Afterwards, cell proliferation, migration, and invasion were examined. Moreover, the autophagy level was assessed by the expression of LC3 and P62. The associated protein expression was determined using Western blot.

Results

PHLDA2 was highly expressed in OC tissues and cells. PHLDA2 knockdown repressed the cell viability and clone-forming ability of OC cells. PHLDA2 knockdown inhibited migration and invasion, as well as the protein expression of MMP-9 and MMP-2 in OC cells. Moreover, LC3 expression was elevated and P62 expression was reduced after PHLDA2 knockdown. Western blot detection further showed decreased phosphorylation levels of PI3K, AKT, and mTOR in PHLDA2-knockdown cells.

Conclusion

These findings reveal that knockdown of PHLDA2 suppresses OC cell proliferation, migration and invasion, while promoting autophagy and inactivating the PI3K/AKT/mTOR pathway, suggesting that PHLDA2 may contribute to OC progression.
目的探讨PHLDA2对体外培养的卵巢癌细胞生物学行为的影响。材料与方法采用qPCR方法对临床OC组织中基于GEPIA分析的PHLDA2 mRNA表达进行验证。在OC细胞中进行了sirna介导的PHLDA2敲低以研究其潜在功能。然后检测细胞增殖、迁移和侵袭。通过LC3和P62的表达来评估自噬水平。Western blot检测相关蛋白表达。结果sphlda2在OC组织和细胞中高表达。敲低PHLDA2抑制OC细胞活力和克隆形成能力。PHLDA2敲低抑制OC细胞的迁移和侵袭,以及MMP-9和MMP-2蛋白的表达。敲低PHLDA2后,LC3表达升高,P62表达降低。Western blot检测进一步显示,phlda2敲低细胞中PI3K、AKT和mTOR的磷酸化水平降低。结论敲低PHLDA2可抑制OC细胞的增殖、迁移和侵袭,促进自噬,使PI3K/AKT/mTOR通路失活,提示PHLDA2可能参与OC的进展。
{"title":"Functional analysis of PHLDA2 in ovarian cancer: Effects on tumor cell behavior and autophagy","authors":"Ren Xu ,&nbsp;Luyang Su ,&nbsp;Yanan Ren ,&nbsp;Xinjun Li ,&nbsp;Shuo Xu ,&nbsp;Jianzhi Su","doi":"10.1016/j.tjog.2025.08.003","DOIUrl":"10.1016/j.tjog.2025.08.003","url":null,"abstract":"<div><h3>Objective</h3><div>We aimed to explore the effect of PHLDA2 on the biological behavior of ovarian cancer (OC) cell in vitro.</div></div><div><h3>Materials and methods</h3><div>Validation of PHLDA2 mRNA expression based on the analysis from GEPIA was performed on clinical OC tissues using qPCR. SiRNA-mediated knockdown of PHLDA2 was conducted in OC cells to investigate its potential functions. Afterwards, cell proliferation, migration, and invasion were examined. Moreover, the autophagy level was assessed by the expression of LC3 and P62. The associated protein expression was determined using Western blot.</div></div><div><h3>Results</h3><div>PHLDA2 was highly expressed in OC tissues and cells. PHLDA2 knockdown repressed the cell viability and clone-forming ability of OC cells. PHLDA2 knockdown inhibited migration and invasion, as well as the protein expression of MMP-9 and MMP-2 in OC cells. Moreover, LC3 expression was elevated and P62 expression was reduced after PHLDA2 knockdown. Western blot detection further showed decreased phosphorylation levels of PI3K, AKT, and mTOR in PHLDA2-knockdown cells.</div></div><div><h3>Conclusion</h3><div>These findings reveal that knockdown of PHLDA2 suppresses OC cell proliferation, migration and invasion, while promoting autophagy and inactivating the PI3K/AKT/mTOR pathway, suggesting that PHLDA2 may contribute to OC progression.</div></div>","PeriodicalId":49449,"journal":{"name":"Taiwanese Journal of Obstetrics & Gynecology","volume":"64 6","pages":"Pages 1043-1049"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145475695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Follow-up of a 4-year-old girl with a favorable outcome and a prenatal history of low-level mosaic trisomy 21 at amniocentesis 对一名4岁女童进行羊膜穿刺术随访,结果良好,产前有低水平镶嵌21三体病史
IF 2.2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-11-01 DOI: 10.1016/j.tjog.2025.09.015
Chih-Ping Chen
{"title":"Follow-up of a 4-year-old girl with a favorable outcome and a prenatal history of low-level mosaic trisomy 21 at amniocentesis","authors":"Chih-Ping Chen","doi":"10.1016/j.tjog.2025.09.015","DOIUrl":"10.1016/j.tjog.2025.09.015","url":null,"abstract":"","PeriodicalId":49449,"journal":{"name":"Taiwanese Journal of Obstetrics & Gynecology","volume":"64 6","pages":"Page 1121"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145476041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Taiwanese Journal of Obstetrics & Gynecology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1